Loading
Loading
Research Overview
Peptide incorporating the p53 HDM2-binding domain fused to a transmembrane-penetrating sequence; proposed to insert into the membranes of cancer cells (which overexpress HDM2) and induce selective membranolysis, while leaving normal cells unaffected.
Overview
PNC-27 combines a 14-amino acid sequence from p53's MDM2-binding domain with a membrane-penetrating sequence to create a chimeric peptide studied in preclinical cancer cell biology research. The rationale for its development draws on the p53 tumour suppressor pathway, in which MDM2 normally promotes p53 degradation and is overexpressed in many cancer cell types. Preclinical studies have examined PNC-27's preferential activity in cancer cell models versus normal cell models in cell culture systems.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, pnc-27 peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Peptide incorporating the p53 HDM2-binding domain fused to a transmembrane-penetrating sequence; proposed to insert into the membranes of cancer cells (which overexpress HDM2) and induce selective membranolysis, while leaving normal cells unaffected.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.